‘Intermittent’ versus ‘continuous’ $ ScvO_{2} $ monitoring in children with septic shock: a randomised, non-inferiority trial
Purpose To compare the effect of ‘intermittent’ central venous oxygen saturation ($ ScvO_{2} $) monitoring with ‘continuous’ $ ScvO_{2} $ monitoring on shock resolution and mortality in children with septic shock. Methods Primary outcome was the achievement of therapeutic goals or shock resolution in the first 6 h. We randomly assigned children < 17 years’ age with septic shock to ‘intermittent $ ScvO_{2} $’ or ‘continuous $ ScvO_{2} $’ groups. All children were subjected to subclavian/internal jugular line insertion and managed as per Surviving Sepsis Campaign Guidelines. To guide resuscitation, we used $ ScvO_{2} $ estimated at other clinical and laboratory parameters were monitored similarly in both groups. Results We enrolled 75 and 77 children [median (IQR) age: 6 (1.5–10) years] in the ‘intermittent’ and ‘continuous’ groups, respectively. Baseline characteristics were comparable between the groups. When compared to the ‘continuous’ group, fewer children in the ‘intermittent’ group achieved shock resolution within first 6 h [19% vs. 36%; relative risk (RR) 0.51; 95% CI 0.29–0.89; risk difference − 18.0%; 95% CI − 32.0 to − 4.0]. The lower bound of confidence interval, however, crossed the pre-specified non-inferiority margin. There was no difference in the proportion of children attaining shock resolution within 24 h (63% vs. 69%; RR 0.86; 95% CI 0.68–1.08) or risk of mortality between the groups (47% vs. 43%; RR 1.06; 95% CI 0.74–1.51). Conclusions Given that a greater proportion of children attained therapeutic end points in the first 6 h, continuous monitoring of $ ScvO_{2} $ should preferably be used to titrate therapy in the first few hours in children with septic shock. In the absence of such facility, intermittent monitoring of $ ScvO_{2} $ can be used to titrate therapy in these children, given the lack of difference in the proportion of patients achieving shock resolution at 24 h or in risk of mortality between the intermittent and continuous groups..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2019 |
---|---|
Erschienen: |
2019 |
Enthalten in: |
Zur Gesamtaufnahme - volume:46 |
---|---|
Enthalten in: |
Intensive care medicine - 46(2019), 1 vom: 28. Nov., Seite 82-92 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Sankar, Jhuma [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
Themen: |
---|
Anmerkungen: |
© Springer-Verlag GmbH Germany, part of Springer Nature 2019 |
---|
doi: |
10.1007/s00134-019-05858-w |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
SPR001248634 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR001248634 | ||
003 | DE-627 | ||
005 | 20230519094036.0 | ||
007 | cr uuu---uuuuu | ||
008 | 201001s2019 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s00134-019-05858-w |2 doi | |
035 | |a (DE-627)SPR001248634 | ||
035 | |a (SPR)s00134-019-05858-w-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Sankar, Jhuma |e verfasserin |0 (orcid)0000-0002-9807-6550 |4 aut | |
245 | 1 | 0 | |a ‘Intermittent’ versus ‘continuous’ $ ScvO_{2} $ monitoring in children with septic shock: a randomised, non-inferiority trial |
264 | 1 | |c 2019 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a © Springer-Verlag GmbH Germany, part of Springer Nature 2019 | ||
520 | |a Purpose To compare the effect of ‘intermittent’ central venous oxygen saturation ($ ScvO_{2} $) monitoring with ‘continuous’ $ ScvO_{2} $ monitoring on shock resolution and mortality in children with septic shock. Methods Primary outcome was the achievement of therapeutic goals or shock resolution in the first 6 h. We randomly assigned children < 17 years’ age with septic shock to ‘intermittent $ ScvO_{2} $’ or ‘continuous $ ScvO_{2} $’ groups. All children were subjected to subclavian/internal jugular line insertion and managed as per Surviving Sepsis Campaign Guidelines. To guide resuscitation, we used $ ScvO_{2} $ estimated at other clinical and laboratory parameters were monitored similarly in both groups. Results We enrolled 75 and 77 children [median (IQR) age: 6 (1.5–10) years] in the ‘intermittent’ and ‘continuous’ groups, respectively. Baseline characteristics were comparable between the groups. When compared to the ‘continuous’ group, fewer children in the ‘intermittent’ group achieved shock resolution within first 6 h [19% vs. 36%; relative risk (RR) 0.51; 95% CI 0.29–0.89; risk difference − 18.0%; 95% CI − 32.0 to − 4.0]. The lower bound of confidence interval, however, crossed the pre-specified non-inferiority margin. There was no difference in the proportion of children attaining shock resolution within 24 h (63% vs. 69%; RR 0.86; 95% CI 0.68–1.08) or risk of mortality between the groups (47% vs. 43%; RR 1.06; 95% CI 0.74–1.51). Conclusions Given that a greater proportion of children attained therapeutic end points in the first 6 h, continuous monitoring of $ ScvO_{2} $ should preferably be used to titrate therapy in the first few hours in children with septic shock. In the absence of such facility, intermittent monitoring of $ ScvO_{2} $ can be used to titrate therapy in these children, given the lack of difference in the proportion of patients achieving shock resolution at 24 h or in risk of mortality between the intermittent and continuous groups. | ||
650 | 4 | |a EGDT |7 (dpeaa)DE-He213 | |
650 | 4 | |a ScvO |7 (dpeaa)DE-He213 | |
650 | 4 | |a Intermittent ScvO |7 (dpeaa)DE-He213 | |
650 | 4 | |a monitoring |7 (dpeaa)DE-He213 | |
650 | 4 | |a Continuous ScvO |7 (dpeaa)DE-He213 | |
650 | 4 | |a monitoring |7 (dpeaa)DE-He213 | |
700 | 1 | |a Singh, Man |4 aut | |
700 | 1 | |a Kumar, Kiran |4 aut | |
700 | 1 | |a Sankar, M. Jeeva |4 aut | |
700 | 1 | |a Kabra, Sushil Kumar |4 aut | |
700 | 1 | |a Lodha, Rakesh |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Intensive care medicine |d Berlin : Springer, 1975 |g 46(2019), 1 vom: 28. Nov., Seite 82-92 |w (DE-627)SPR001167375 |w (DE-600)1459201-0 |x 1432-1238 |7 nnns |
773 | 1 | 8 | |g volume:46 |g year:2019 |g number:1 |g day:28 |g month:11 |g pages:82-92 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s00134-019-05858-w |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |d 46 |j 2019 |e 1 |b 28 |c 11 |h 82-92 |